Evaluation of the Hepatoprotective Activity of Serinolamide A against Paracetamol-Induced Hepatotoxicity in Rats
Paracetamol-induced hepatotoxicity is characterized by oxidative stress, inflammatory responses, and progressive liver damage. The present study aimed to evaluate the hepatoprotective effects of Serinolamide A against paracetamol-induced hepatotoxicity in rats. Experimental hepatotoxicity was induced by paracetamol administration, and rats were treated orally with Serinolamide A (1, 5, and 10 mg/kg) for 28 consecutive days. Liv52 (70 mg/kg, p.o.) was used as the standard drug. Body weight, liver weight, serum biochemical parameters, oxidative stress markers, pro-inflammatory cytokines, and histopathological changes were evaluated. Treatment with Serinolamide A significantly ameliorated paracetamolinduced alterations and restored body and liver weights. Furthermore, Serinolamide A enhanced antioxidant defense by increasing superoxide dismutase, catalase, and reduced glutathione activities and reduced lipid peroxidation. The treatment also attenuated inflammatory responses by decreasing tumor necrosis factor-α and interleukin-6 levels. Histopathological examination revealed marked protection against paracetamol-induced hepatic damage. The observed effects were dose-dependent, with the 10 mg/kg dose showing effects comparable to those of Liv52. These findings suggest that Serinolamide A possesses significant hepatoprotective activity, which may be attributed to its antioxidant and anti-inflammatory properties, and could represent a promising therapeutic candidate for the management of drug-induced liver injury